Theranexus
Clinical-stage biopharmaceutical company developing treatments for rare neurological disorders.
ALTHX | PA
Overview
Corporate Details
- ISIN(s):
- FR0013286259
- LEI:
- 969500BFCV6IC7MFQP20
- Country:
- France
- Address:
- 60 AVENUE ROCKEFELLER, 69008 LYON
- Website:
- https://www.theranexus.com/en/
- Sector:
- Manufacturing
Description
THX Pharma (formerly Theranexus) is an innovative, clinical-stage biopharmaceutical company that emerged from the French Alternative Energies and Atomic Energy Commission (CEA). The company specializes in developing treatments for rare neurological disorders. It leverages a unique platform for the identification and characterization of advanced therapy drug candidates. Its lead program is a drug candidate in clinical development for Batten disease, a rare neurodegenerative disorder.
Unlock This Filing & Millions More
You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.
Filings
| Date | Filing | Language | Size | Actions | |
|---|---|---|---|---|---|
| 2020-12-28 18:00 |
THERANEXUS ANNOUNCES ITS FINANCIAL CALENDAR FOR 2021
|
English | 418.1 KB | ||
| 2020-12-28 18:00 |
THERANEXUS PUBLIE SON AGENDA FINANCIER 2021
|
French | 651.3 KB | ||
| 2020-12-18 08:00 |
THERANEXUS, LE CENTRE DE RECHERCHE EN NEUROSCIENCES DE LYON ET LE CERMEP ANNONC…
|
French | 426.8 KB | ||
| 2020-12-18 08:00 |
THERANEXUS, LYON NEUROSCIENCE RESEARCH CENTER AND CERMEP ANNOUNCE THE CREATION …
|
English | 418.4 KB | ||
| 2020-11-19 07:30 |
THE FOOD AND DRUG ADMINISTRATION (FDA) ISSUES A FAVORABLE OPINION ON THE PRECLI…
|
English | 317.2 KB | ||
| 2020-11-19 07:30 |
LA FOOD AND DRUG ADMINISTRATION (FDA) REND UN AVIS FAVORABLE AU PLAN DE DEVELOP…
|
French | 839.1 KB | ||
| 2020-11-04 18:00 |
PRESENTATION OF THE RESULTS OF THE PHASE IB CLINICAL STUDY OF THN201 FOR ALZHEI…
|
English | 322.3 KB | ||
| 2020-11-04 18:00 |
PRÉSENTATION DES RÉSULTATS DE L'ÉTUDE CLINIQUE DE PHASE 1b AVEC THN201 DANS LA …
|
French | 374.4 KB | ||
| 2020-10-21 18:00 |
THERANEXUS ET LA FONDATION BBDF OBTIENNENT LE STATUT DE ' MÉDICAMENT ORPHELIN' …
|
French | 689.1 KB | ||
| 2020-10-15 18:00 |
THERANEXUS PUBLIE SA POSITION DE TRÉSORERIE AU 30 SEPTEMBRE 2020
|
French | 1.1 MB | ||
| 2020-09-29 18:00 |
RESULTATS DU PREMIER SEMESTRE 2020
|
French | 401.5 KB | ||
| 2020-09-09 18:00 |
THERANEXUS PRESENTS ITS LATEST SCIENTIFIC NEWS
|
English | 710.1 KB | ||
| 2020-09-09 18:00 |
THERANEXUS FAIT LE POINT SUR SON ACTUALITÉ SCIENTIFIQUE
|
French | 516.9 KB | ||
| 2020-09-07 18:00 |
INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D'ACTIONS COMPOSANT L…
|
French | 249.7 KB | ||
| 2020-09-07 18:00 |
DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
|
English | 244.9 KB |
Automate Your Workflow. Get a real-time feed of all Theranexus filings delivered via API.
Market Data
Market Data Not Available
Financials & KPIs
Unlock Full Financials for Theranexus
This data is available as part of our premium data solutions. Contact our team for access.
Need More History? Access decades of standardized financials for Theranexus via our API.
Insider Transactions
| Date | Insider Name | Position | Type | Shares | Value |
|---|---|---|---|---|---|
| No insider transactions recorded for this company. | |||||
Peer Companies
